Camurus AB (publ) (CAMX.ST)
SEK 632.0
(1.77%)
SEK 632.0
(1.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.16 Billion SEK | -116.07% |
| 2022 | -539.32 Million SEK | -39.75% |
| 2021 | -385.91 Million SEK | 11.55% |
| 2020 | -436.31 Million SEK | -31.65% |
| 2019 | -331.41 Million SEK | -146.63% |
| 2018 | -134.37 Million SEK | 57.28% |
| 2017 | -314.52 Million SEK | 38.16% |
| 2016 | -508.59 Million SEK | 28.98% |
| 2015 | -716.09 Million SEK | -1278642.86% |
| 2014 | -56 Thousand SEK | -1020.0% |
| 2013 | -5000.00 SEK | -66.67% |
| 2012 | -3000.00 SEK | -50.0% |
| 2011 | -2000.00 SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.25 Billion SEK | -93.17% |
| 2024 Q2 | -2.54 Billion SEK | -13.11% |
| 2023 Q3 | -1.12 Billion SEK | -79.9% |
| 2023 FY | -1.16 Billion SEK | -116.07% |
| 2023 Q1 | -561.82 Million SEK | -4.17% |
| 2023 Q4 | -1.16 Billion SEK | -3.26% |
| 2023 Q2 | -627.31 Million SEK | -11.66% |
| 2022 Q1 | -375.86 Million SEK | 2.61% |
| 2022 FY | -539.32 Million SEK | -39.75% |
| 2022 Q4 | -539.32 Million SEK | -9.08% |
| 2022 Q3 | -494.4 Million SEK | -21.83% |
| 2022 Q2 | -405.83 Million SEK | -7.97% |
| 2021 Q4 | -385.91 Million SEK | 3.53% |
| 2021 Q1 | -403.6 Million SEK | 7.5% |
| 2021 Q2 | -398.95 Million SEK | 1.15% |
| 2021 Q3 | -400.02 Million SEK | -0.27% |
| 2021 FY | -385.91 Million SEK | 11.55% |
| 2020 FY | -436.31 Million SEK | -31.65% |
| 2020 Q2 | -196.85 Million SEK | 25.73% |
| 2020 Q3 | -451.98 Million SEK | -129.6% |
| 2020 Q4 | -436.31 Million SEK | 3.47% |
| 2020 Q1 | -265.04 Million SEK | 20.03% |
| 2019 FY | -331.41 Million SEK | -146.63% |
| 2019 Q4 | -331.41 Million SEK | -99.5% |
| 2019 Q3 | -166.11 Million SEK | 35.12% |
| 2019 Q2 | -256.03 Million SEK | 32.4% |
| 2019 Q1 | -378.76 Million SEK | -181.87% |
| 2018 Q3 | -216.34 Million SEK | -8.67% |
| 2018 Q2 | -199.09 Million SEK | 25.33% |
| 2018 Q1 | -266.63 Million SEK | 15.23% |
| 2018 FY | -134.37 Million SEK | 57.28% |
| 2018 Q4 | -134.37 Million SEK | 37.89% |
| 2017 Q3 | -369.74 Million SEK | 10.55% |
| 2017 FY | -314.52 Million SEK | 38.16% |
| 2017 Q1 | -463.8 Million SEK | 8.81% |
| 2017 Q4 | -314.52 Million SEK | 14.94% |
| 2017 Q2 | -413.36 Million SEK | 10.88% |
| 2016 FY | -508.59 Million SEK | 28.98% |
| 2016 Q4 | -508.59 Million SEK | 1.86% |
| 2016 Q3 | -518.24 Million SEK | 5.6% |
| 2016 Q2 | -548.98 Million SEK | 4.01% |
| 2016 Q1 | -571.91 Million SEK | 20.13% |
| 2015 Q1 | 56 Thousand SEK | 200.0% |
| 2015 Q4 | -716.09 Million SEK | -537.4% |
| 2015 FY | -716.09 Million SEK | -1278642.86% |
| 2015 Q3 | -112.34 Million SEK | 0.0% |
| 2014 Q4 | -56 Thousand SEK | 0.0% |
| 2014 FY | -56 Thousand SEK | -1020.0% |
| 2013 FY | -5000.00 SEK | -66.67% |
| 2012 FY | -3000.00 SEK | -50.0% |
| 2011 FY | -2000.00 SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | -3410.039% |
| Biovica International AB (publ) | -58.73 Million SEK | -1883.985% |
| Cantargia AB (publ) | -139.74 Million SEK | -733.888% |
| CombiGene AB (publ) | -101.44 Million SEK | -1048.79% |
| Cyxone AB (publ) | -16.67 Million SEK | -6890.6% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -39110.397% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -3866.015% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -1985.197% |
| Fluicell AB (publ) | -2.76 Million SEK | -42076.366% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | -254.136% |
| Mendus AB (publ) | -96.29 Million SEK | -1110.182% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -743.54% |
| I-Tech AB | -83.26 Million SEK | -1299.598% |
| Intervacc AB (publ) | -88.16 Million SEK | -1221.839% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -3549.992% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 2289.529% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -6014.024% |
| OncoZenge AB (publ) | -12.62 Million SEK | -9128.898% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -2233.747% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 801.682% |
| Lipum AB (publ) | -8.46 Million SEK | -13666.486% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -2229.688% |
| Ziccum AB (publ) | -2.13 Million SEK | -54431.259% |
| BioArctic AB (publ) | -606.58 Million SEK | -92.113% |
| Genovis AB (publ.) | -43.94 Million SEK | -2552.04% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -1291.559% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -2859.05% |
| Aptahem AB (publ) | 2.9 Million SEK | 40164.504% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | -249.3% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -799.906% |
| Kancera AB (publ) | -45.69 Million SEK | -2450.409% |
| Saniona AB (publ) | 40.44 Million SEK | 2981.136% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -2477.201% |
| AcouSort AB (publ) | -23.98 Million SEK | -4758.388% |
| Xintela AB (publ) | -7.8 Million SEK | -14822.948% |
| Abliva AB (publ) | -57.24 Million SEK | -1935.872% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -1317.646% |
| Amniotics AB (publ) | -5.63 Million SEK | -20591.282% |
| 2cureX AB (publ) | -13.4 Million SEK | -8594.568% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -53825.636% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 21680.241% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 965.081% |
| Biosergen AB | -1.88 Million SEK | -61787.042% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 5781.78% |
| Corline Biomedical AB | -17.01 Million SEK | -6750.065% |
| NextCell Pharma AB | -46.79 Million SEK | -2390.527% |
| Nanologica AB (publ) | -9.38 Million SEK | -12313.006% |
| LIDDS AB (publ) | -13.51 Million SEK | -8524.43% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | -498.527% |
| BioInvent International AB (publ) | -236.3 Million SEK | -393.15% |
| SynAct Pharma AB | -61.75 Million SEK | -1786.934% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -5341.667% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -8708.807% |
| Alzinova AB (publ) | -21.22 Million SEK | -5390.121% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -5504.449% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -1641.382% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -22392.781% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -1291.592% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -126154.93% |
| Simris Alg AB (publ) | 85.07 Million SEK | 1469.771% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -1319.649% |